{{Rsnum
|rsid=28399433
|Gene=CYP2A6
|Chromosome=19
|position=40850474
|Orientation=minus
|GMAF=0.1336
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=CYP2A6
}}[[rs28399433]], also known as -47A>C, is a SNP in the [[CYP2A6]] gene.

{{PMID Auto
|PMID=19339270
|Title=Genetic Associations of 115 Polymorphisms with Cancers of the Upper Aerodigestive Tract across 10 European Countries: The ARCAGE Project.
}}

{{PharmGKB
|RSID=rs28399433
|Name_s=CYP2A6:52553A>G
|Gene_s=CYP2A6
|Feature=Intron
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2a6/variant.jsp
|Annotation=This variant results in decreased enzyme expression and activity, which affects nicotine and coumarin metabolism; part of the CYP2A6*9 haplotype.
|Drugs=coumarin; nicotine
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145203
}}

{{PMID Auto
|PMID=22046326
|Title='Smoking Genes': A Genetic Association Study
|OA=1
}}

{{PMID|19371316|OA=1
}} CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

{{PMID|19659438|OA=1
}} CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs28399433
|overall_frequency_n=736
|overall_frequency_d=10754
|overall_frequency=0.0684396
|n_genomes=13
|n_genomes_annotated=0
|n_haplomes=13
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24080498
|Title=Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}